Delivery Order SPE2DR25D2005-SPE2DR26FE6S0
Award Date 11/12/25
Potential Completion Date 11/13/25
Potential Value $16K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $53,776.82 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen 40 mg/0.4 mL, a biologic medication used primarily for rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a non-competitive set-aside procurement conducted under the company's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $15,740.52 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. This competitively awarded, firm fixed-price delivery order was issued on November 13, 2025, with an ultimate completion date of November 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency Medical Supply Chain for $34,644.30 to supply HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other autoimmune conditions. The award, issued on July 15, 2025, with completion targeted for July 16, 2025, employs a firm fixed price structure with no set-aside designation, indicating competitive award selection. The contract will be...
- The Defense Logistics Agency awarded a $1,691.08 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens containing 40 mg/0.4 mL, a biologic immunosuppressant medication commonly used to treat autoimmune conditions. This non-set-aside, competitively awarded delivery order was issued on November 4, 2025, with an ultimate completion date of November 5, 2025, and carries firm fixed pricing. The order will be fulfilled from AmerisourceBergen's corporate office location...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, valued at $8,435.70, represents an uncompeted non-set-aside award and is scheduled for completion by July 16, 2025. The contract will be fulfilled from AmerisourceBergen's distribution...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Humira (Adalimumab) prefilled pens at 40 mg/0.4 mL, a biologic medication used to treat autoimmune conditions. This firm fixed-price delivery order, valued at $5,264.52, represents a non-competitive set-aside award and is scheduled for completion by November 13, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a $13,075.97 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens, 40 mg/0.4 mL dosage. This contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Medical Supply Chain issued a delivery order valued at $20,224.05 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed price, non-set-aside contract awarded on July 14, 2025, with an ultimate completion date of July 15, 2025. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of HUMIRA (adalimumab) pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. This firm fixed-price delivery order, valued at $3,770.00, represents a non-set-aside competitive award and is scheduled for completion by April 22, 2025. The product will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...